PASSAGE BIO INC (PASG) Stock Price, Quote, News and Overview
NASDAQ:PASG - Nasdaq - US7027121000 - Common Stock - Currency: USD
PASG Quote, Performance and Key Statistics
0.46
-0.01 (-2.13%)
The current stock price of PASG is 0.46 USD. In the past month the price decreased by -21.04%. In the past year, price decreased by -68.28%.
PASG Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About PASG
Company Profile
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 58 full-time employees. The company went IPO on 2020-02-28. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Company Info
PASSAGE BIO INC
One Commerce Square, 2005 Market Street, 39Th Floor
PHILADELPHIA PENNSYLVANIA 19103 US
CEO: Bruce Goldsmith
Employees: 58
Company Website: https://www.passagebio.com/
Investor Relations: https://investors.passagebio.com/
Phone: 12678660312
PASSAGE BIO INC / PASG FAQ
What is the stock price of PASSAGE BIO INC today?
The current stock price of PASG is 0.46 USD. The price decreased by -2.13% in the last trading session.
What is the ticker symbol for PASSAGE BIO INC stock?
The exchange symbol of PASSAGE BIO INC is PASG and it is listed on the Nasdaq exchange.
On which exchange is PASG stock listed?
PASG stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PASSAGE BIO INC stock?
11 analysts have analysed PASG and the average price target is 7.14 USD. This implies a price increase of 1452.17% is expected in the next year compared to the current price of 0.46. Check the PASSAGE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PASSAGE BIO INC worth?
PASSAGE BIO INC (PASG) has a market capitalization of 28.59M USD. This makes PASG a Nano Cap stock.
How many employees does PASSAGE BIO INC have?
PASSAGE BIO INC (PASG) currently has 58 employees.
Should I buy PASSAGE BIO INC (PASG) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PASG, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PASG, evaluating the profitability, health, valuation and growth aspects
- PASSAGE BIO INC (PASG) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PASSAGE BIO INC (PASG) Sales and EPS estimates to see what analysts future expectations are.
- PASSAGE BIO INC (PASG) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PASSAGE BIO INC (PASG) Insider and Institutional Ownership to learn about the owners and their transactions.
- PASSAGE BIO INC (PASG) Stock Chart to make your own analysis
- PASSAGE BIO INC (PASG) Latest news and press-releases to stay up to date.
Does PASSAGE BIO INC (PASG) stock pay dividends?
PASG does not pay a dividend.
When does PASSAGE BIO INC (PASG) report earnings?
PASSAGE BIO INC (PASG) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of PASSAGE BIO INC (PASG)?
PASSAGE BIO INC (PASG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.17).
What is the Short Interest ratio of PASSAGE BIO INC (PASG) stock?
The outstanding short interest for PASSAGE BIO INC (PASG) is 3.29% of its float. Check the ownership tab for more information on the PASG short interest.
PASG Technical Analysis
PASG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PASG. PASG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PASG Financial Highlights
Over the last trailing twelve months PASG reported a non-GAAP Earnings per Share(EPS) of -1.17. The EPS increased by 42.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.56% | ||
| ROE | -94.61% | ||
| Debt/Equity | 0 |
PASG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to PASG. The Buy consensus is the average rating of analysts ratings from 11 analysts.